Pharmaceutical research in paediatric populations and the new EU Paediatric Legislation: An industry perspective

Child and Adolescent Psychiatry and Mental Health

Volumn 2, Issue , 2008, Pages

  Auby, Philippe ^a  

^a Lundbeck   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTHORITY; CLINICAL RESEARCH; DRUG DEVELOPMENT; DRUG DOSE; DRUG LEGISLATION; DRUG RESEARCH; DRUG USE; EUROPEAN UNION; PEDIATRICS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; UNITED STATES;

EID: 58149501184     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-2-38     Document Type: Article

References (24)

1. Hoppu K Paediatric clinical psychopharmacology - at the beginning of a new era Eur J Clin Pharmacol 2008, 64:201-205. 10.1007/s00228-007-0390-5 17972069
2. Conroy S Choonara I Impicciatore P Mohn A Arnell H Rane A Knoeppel C Seyberth H Pandolfini C Raffaelli MP Rocchi F Bonati M Jong G de Hoog M Anker van den J Survey of unlicensed and off label drug use in paediatric wards in European countries BMJ 2000, 320:79-82. 27251 10625257 10.1136/bmj.320.7227.79
3. European Medicines Agency (EMEA) The European paediatric initiative: History of the Paediatric Regulation EMEA/17967/04 Rev 1. July 2007
4. European Commission Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use 2006.
5. Vitiello B Research in child and adolescent psychopharmacology: Recent accomplishments and new challenges Psychopharmacology 2007, 191:5-13. 10.1007/s00213-006-0414-3 16718480
6. Fegert JM Vitiello B Peer-reviewed, high quality, worldwide information on all topics relevant to child and adolescent mental health Child Adolesc Psychiatry Mental Health 2007, 1:1. 10.1186/1753-2000-1-1
7. Wong ICK Murray ML Camilleri-Novak D Stephens P Increased prescribing trends of paediatric psychotropic medications Arch Dis Child 2004, 89:1131-1132. 1719746 15557050 10.1136/adc.2004.050468
8. Weller EB Weller RA Danielyan AK Mood disorders in adolescents Textbook of Child and Adolescent Psychiatry Washington, DC: American Psychiatric Publishing, Inc Wiener JM, Dulcan MK 3 2004:437-481.
9. Cohen D Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned? Psychother Psychosom 2007, 76:5-14. 10.1159/000096360 17170559
10. Vitiello B Developmental aspects of pediatric psychopharmacology Clinical Manual of Child and Adolescent Psychopharmacology American Psychiatry Publishing, Inc Findling RL 2008:1-31.
11. Axelson DA Perel JM Birmaher B Rudolph G Nuss S Yurasits L Bridge J Brent DA Platelet Serotonin Reuptake Inhibition and Response to SSRIs in Depressed Adolescents Am J Psychiatry 2005, 162:802-804. 10.1176/ appi.ajp.162.4.802 15800159
12. Moreno C Arango C Parellada M Shaffer D Bird H Antidepressants in child and adolescent depression: Where are the bugs? Acta Psychiatr Scand 2007, 115:184-195. 10.1111/j.1600-0447.2006.00951.x 17302618
13. Emslie GJ Bose A Ventura D Tourkodimitiris S Escitalopram in the Treatment of Adolescent Depression Poster presented at the Annual Meeting of the American Psychiatric Association, Washington DC 2008.
14. Wagner KD Pharmacotherapy for major depression in children and adolescents Progr Neuropsychopharmacol Biol Psychiatry 2005, 29:819-826. 10.1016/j.pnpbp.2005.03.005
15. Moreno C Roche AM Greenhill LL Pharmacotherapy of child and adolescent depression Child Adolesc Psychiatric Clin N Am 2006, 15:977-998. 10.1016/ j.chc.2006.05.006
16. Usala T Clavenna A Zuddas A Bonati M Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: A systematic review and meta-analysis European Neuropsychopharmacology 2008, 18:62-73. 10.1016/j.euroneuro.2007.06.001 17662579
17. Findling RL McNamara NK Stansbrey RJ Feeny NC Young CM Peric FV Youngstrom EA The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression J Child Adolesc Psychopharmacol 2006, 16:131-145. 10.1089/cap.2006.16.131 16553534
18. Atuah KN Hughes D Pirmohamed M Clinical pharmacology: Special safety considerations in drug development and pharmacovigilance Drug Saf 2004, 27:535-554. 10.2165/00002018-200427080-00006 15154826
19. Allen AJ Michelson D Drug development process for a product with a primary pediatric indication J Clin Psychiatry 2002, 63(Suppl 12):44-49. 12562061
20. International Conference on Harmonisation (ICH) ICH Harmonised tripartite Guideline E11: Clinical investigation of medicinal products in the pediatric population 2000. http://www.ich.org/cache/compo/ 475-272-1.html#E11
21. European Commission Ethical considerations for clinical trials on medicinal products conducted with the paediatric population: Recommendations of the ad hoc group for the development of implementing guidelines for Directive 2001/20/EC relating to good clinical practice in the conduct of clinical trials on medicinal products for human use Final 2008. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/ vol-10/ethical_considerations.pdf
22. Caron C Rutter M Comorbidity in child psychopathology: Concepts, issues and research strategies J Child Psychol Psychiatry 1991, 32:1063-1080. 10.1111/j.1469-7610.1991.tb00350.x 1787137
23. Apter J Auby P Tao D Fisher T A Breakthrough for an Old Model: The European Pediatric Initiative Poster presented at the International Society for CNS Clinical Trials and Methodology (ISCTM), Brussels 2007.
24. Li JS Eisenstein EL Grabowski HG Reid ED Mangum B Schulman KA Goldsmith JV Murphy MD Califf RM Benjamin DK Jr Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program JAMA 2007, 297:480-488. 10.1001/jama.297.5.480 17284698